Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Does Ranolazine Decrease Biomarkers That Indicate Evidence of Myocardial Damage in Diabetics With Stable Ischemic Heart Disease? A Double-blinded, Randomized, Placebo Controlled Trial

NCT02611596 is registered in ClinicalTrials.gov with Walter Reed National Military Medical Center as lead sponsor.

NCT NCT02611596
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02611596 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Does Ranolazine Decrease Biomarkers That Indicate Evidence of Myocardial Damage in Diabetics With Stable Ischemic Heart Disease? A Double-blinded, Randomized, Placebo Controlled Trial
Lead sponsor
Walter Reed National Military Medical Center
Phase
Not applicable
Overall status
Withdrawn
Start date
November 30, 2016
Completion date
November 30, 2019
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

silent myocardial ischemia, type 2 diabetes